The Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization based in New York City (29 Broadway, 4th Floor, New York, NY 10006-3201). Founded in 1953, CRI is a top-rated charitable organization dedicated to advancing cancer immunotherapy research. The organization operates under the tagline "For a World Immune to Cancer™" and focuses on fueling the discovery and development of immunotherapies across all cancer types.
Financial Overview
From 2024 IRS Form 990-PF · View filing
Total Assets
$133.7M
-3.1% YoY
Annual Giving
$15.8M
-37.1% YoY
Grant Count
33
-26.7% YoY
Avg Grant Size
$478K
-14.2% YoY
Mission & Focus Areas
Mission: SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all cancers.
CRI's work centers on cancer immunology and immunotherapy research. The organization is committed to driving scientific advancement in understanding how the immune system can be mobilized to fight cancer, with particular emphasis on:
- Understanding why some patients respond to immunotherapy treatment while others do not
- Expanding clinical trials testing immunotherapy across more cancer types
- Identifying optimal treatment combinations with the greatest potential benefit to patients
- Supporting mid-career and early-career scientists in cancer immunology research
Grantmaking
CRI operates multiple grant and fellowship programs:
Ready to take the next step with Cancer Research Institute Inc?
Geographic Focus
Where this funder awards grants
CRI's grant-making activities focus primarily on New York, Massachusetts, and California, though the organization supports cancer immunotherapy research scientists worldwide. CRI has invested over $570 million in research scientists globally.
Grant Distribution by State
States
Cities
Financial History
Multi-year comparison from IRS filings
Most Recent Financial Data (2024):
- Total Assets: $133,734,670
- Total Revenues: $23,964,638
- Total Expenses: $32,820,896
- Number of Employees: 32
Historical Financial Performance (2023):
- Revenue: $32.3 million
- Expenses: $38.6 million
- Total Assets: $138 million
Program Spending: CRI maintains one of the lowest overhead expense ratios among nonprofit organizations. Historically, between 83 and 90 cents of every dollar donated goes to cancer research and medical education programs.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Assets | $133,734,670 | $138,008,864 | $130,438,312 |
| Revenue | $23,964,638 | $32,295,259 | $33,675,150 |
| Expenses | $32,820,896 | $38,552,663 | $31,314,716 |
| Qualifying Distributions | — | — | — |
| Net Investment Income | $3,783,274 | $1,191,003 | $4,910,453 |
| Distributable Amount | — | — | — |
Giving Over Time
Total grant dollars and number of grants per year
Grant Insights
How this funder distributes its grants
Top Recipients
Top 10 recipients in 2024
Grant Size Distribution
184 grants across all recorded years
Open Grants
6 open opportunities from Cancer Research Institute Inc
Clinic & Laboratory Integration Program (CLIP) Grant
CANCER RESEARCH INSTITUTE INC
Amount
Up to US $300,000
Deadline
Rolling / Open
CRI Clinical Innovator
CANCER RESEARCH INSTITUTE INC
Amount
Varies
Deadline
Rolling / Open
CRI Irvington Postdoctoral Fellowship Grant
CANCER RESEARCH INSTITUTE INC
Amount
Up to US $233,000
Deadline
Rolling / Open
Giving History
Grant recipients and amounts by year
No grants recorded for .
Leadership & Key People
Leadership team and compensation from IRS filings
Chief Executive Officer: Alicia Zhou
Compensation Overview
From 2024 IRS filing
From 2024 filing
| Name | Title | Hours | Compensation |
|---|---|---|---|
| PAUL C SHIVERICK | CHAIRMEN | 5 | — |
| ANDREW K TSAI | CHAIRMEN | 5 | — |
| DONALD J GOGEL | VICE CHAIRMEN | 3 | — |
| EDGAR R BERNER | VICE CHAIRMEN | 3 | — |
| GEOFFREY O COLEY | TREASURER | 3 | — |
| THOMAS G MENDELL | SECRETARY | 1 | — |
| TONY ALVAREZ II | TRUSTEE | 0.5 | — |
| YACOV ARNOPOLIN | TRUSTEE | 4 | — |
| PETER L BLOOM | TRUSTEE | 4 | — |
| BRIAN J BRILLE | TRUSTEE | 1 | — |
| MICHAEL R CRAWFORD | TRUSTEE (THRU 4/2024) | 1 | — |
| W ROBERT DAHL | TRUSTEE | 1 | — |
| MAXWELL DAVID | TRUSTEE | 0.25 | — |
| GLENN J DESIMONE | TRUSTEE (THRU 7/2023) | 1 | — |
| SEAN P FAHEY | TRUSTEE | 1 | — |
| WILLIAM S GOLDBERG | TRUSTEE | 0.25 | — |
| OLIVER R GRACE JR | TRUSTEE | 1 | — |
| SANDRA COUDERT GRAHAM | TRUSTEE | 0.5 | — |
| MICHAEL M KELLEN | TRUSTEE | 1 | — |
| SARAH KIM | TRUSTEE | 3 | — |
| FERN LAZAR | TRUSTEE | 3 | — |
| ALEXANDER P LYNCH | TRUSTEE (THRU 7/2023) | 1 | — |
| SANDRA OZOLA | TRUSTEE | 0.25 | — |
| MICHAEL J PETRICK | TRUSTEE | 0.5 | — |
| LIEF D ROSENBLATT | TRUSTEE | 0.25 | — |
| ANAND SHAH MD | TRUSTEE | 0.25 | — |
| ADAM SHAPIRO | TRUSTEE | 0.25 | — |
| FRANK V SICA | TRUSTEE | 1 | — |
| JAMES A STERN | TRUSTEE | 1 | — |
| ROBERT S STOLAR | TRUSTEE | 1 | — |
| MICHAEL B TARGOFF | TRUSTEE | 1 | — |
| DIANE TUFT | TRUSTEE | 1 | — |
| LAUREN S VERONIS | TRUSTEE | 3 | — |
| RONALD G WEINER | TRUSTEE | 1 | — |
| JIM WEISS | TRUSTEE | 4 | — |
| PETER ZHOU | TRUSTEE | 5 | — |
| ALFRED R MASSIDAS TO 22025 | CFO & DIRECTOR OF HUMAN RESOURCES | 40 | $347,437 |
| JILL O'DONNELL TORMEY TO 824 | CEO & DIRECTOR OF SCIENTIFIC AFFAIRS | 40 | $539,137 |
| ALICIA ZHOU PHD START 92024 | CEO | 40 | — |
| KATHRYN BEELEY START 22025 | CFO | 40 | — |
| DEANNE T MARBACH | DIRECTOR OF MAJOR GIFTS | 40 | $155,690 |
| JAY R CAMPBELL | MANAGING DIR OF CRI CLINICAL ACCELERATOR | 40 | $284,937 |
| LYNNE A RAPINO | CHIEF PROGRAM OFFICER | 40 | $287,287 |
| RUPINDER KAUR | CHIEF INFORMATION OFFICER | 40 | $247,910 |
| SHARON S SLADE | CHIEF MARKETING OFFICER | 40 | $273,403 |
| BRIAN M BREWER | CHIEF COMMUNICATIONS OFFICER | 40 | $148,135 |
| MARLA S LAWSON | ASSOC DIR OF CORPORATE RELATIONS | 40 | $136,015 |
| QING HUA ZHANG | CONTROLLER | 40 | $147,203 |
| SAMIK K UPADHAYA | ASST DIRECTOR, SCIENTIFIC AFFAIRS | 40 | $145,770 |
| SHASELL NEGRON | ASSOC DIR, COMMUNITY FUNDRAISING | 40 | $126,437 |
Recent News & Activity
Recent developments and announcements
**Israel Cancer Research Fund Partnership:** Co-funding grant to address immunotherapy resistance in melanoma
Israel Cancer Research Fund and Cancer Research Institute Announce Co-Funding**Multi-Organization Aging & Cancer Research Partnership:** Announced $2.5 million in collaborative funding for aging and cancer research
Israel Cancer Research Fund and Cancer Research Institute Announce Co-Funding**Kidney Cancer Association Collaboration:** Co-funding agreement for kidney cancer immunotherapy research
Israel Cancer Research Fund and Cancer Research Institute Announce Co-Funding**IGNITE Award Launch:** Introduced new five-year funding initiative to support next-generation cancer immunotherapy leaders
Israel Cancer Research Fund and Cancer Research Institute Announce Co-Funding**AI-Driven Immuno-Oncology Initiative:** Launched transformative initiative powered by 10x Genomics technology
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology**CRI Discovery Engine:** Introduced a first-of-its-kind foundational database for cancer immunotherapy research
Israel Cancer Research Fund and Cancer Research Institute Announce Co-FundingSubject Areas
Focus areas based on grantmaking activity
Data last updated April 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.
What could you do with Cancer Research Institute Inc on Grantable?
- Assess strategic fit with your organization
- Draft a tailored letter of inquiry
- Find open RFPs from this funder
- Monitor for new funding opportunities